Johnson Pharmacare Ltd (532154)
Latest quarterly results (Q4 FY26)
In its latest reported quarter, Q4 FY26, Johnson Pharmacare's revenue was ₹0.0 Cr, and net profit ₹-56.0 Cr (a bigger loss than a year earlier).
| Q4 FY26 (₹ Cr) | Value | YoY vs Q4 FY25 | QoQ |
|---|---|---|---|
| Revenue | ₹0.0 | — | — |
| Operating profit | ₹-43.0 | — | — |
| Net profit | ₹-56.0 | loss widened | — |
| EPS (₹) | -1.01 | loss widened | — |
📢 Recent Corporate Announcements
Johnson Pharmacare Ltd has filed an undertaking with the BSE stating that Regulation 32 of SEBI (LODR) is not applicable for the quarter ended June 30, 2026. The company confirmed it did not raise any funds through public, rights, or preferential issues during this period. As a result, there are no deviations or variations to report regarding the utilization of proceeds. This filing is routine for companies that have not conducted recent capital raises.
- Regulation 32 compliance is not applicable for the quarter ended June 30, 2026
- Zero shares were issued via public, rights, or preferential routes during the quarter
- Company maintains a market capitalization of Rs 27 Cr despite zero TTM revenue
- TTM net loss stands at Rs 56 Cr as of the latest financial context
Johnson Pharmacare submitted its un-audited financial results for the quarter ended June 30, 2026. The statutory auditor, VRSK & Associates, issued a significant observation stating that the results were not prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act. This is critical given the company's existing financial distress, including a TTM revenue of Rs 0 Cr and a net worth of Rs 0 Cr.
- Statutory auditor noted that financial results were not prepared in accordance with Ind AS standards
- Company reported TTM revenue of Rs 0 Cr and a TTM net loss of Rs 56 Cr
- Debt stands at Rs 21 Cr against a market capitalization of only Rs 27 Cr
- Net worth is currently reported at Rs 0 Cr, indicating severe financial instability
- Board meeting for result approval concluded at 05:30 P.M. on August 13, 2026
Johnson Pharmacare approved its un-audited financial results for the quarter ended June 30, 2026. The company continues to operate in a distressed financial state, with TTM revenue at Rs 0 Cr and a massive FY26 net loss of Rs 56 Cr, which exceeds its current market capitalization of Rs 27 Cr. Notably, the statutory auditor's limited review report stated that the results were not prepared in accordance with Ind AS standards. The company also confirmed no funds were raised through public or preferential issues during the quarter.
- Board approved un-audited financial results for the quarter ended June 30, 2026
- Statutory auditor VRSK & Associates noted results were not prepared in accordance with Ind AS under Section 133 of the Companies Act
- Company reported zero revenue (Rs 0 Cr) for the entire TTM period ending March 2026
- FY26 net loss of Rs 56 Cr is significantly higher than the company's total market cap of Rs 27 Cr
- Net worth remains at Rs 0 Cr with a debt burden of Rs 21 Cr as per latest financial context
Johnson Pharmacare Ltd has informed the exchange that its Board of Directors approved shifting the company's registered office within Ahmedabad on August 11, 2026. The office moves from Navrangpura to Titanium City Centre Mall in the Satellite area. This is a purely administrative change and does not impact the company's business operations. The company currently reports zero revenue and a net loss of ₹56 Cr for the TTM period ending March 2026.
- Board meeting held on August 11, 2026, from 05:35 p.m. to 06:45 p.m. to approve the shift.
- Registered office relocated from Navrangpura (380009) to Satellite (380015) within Ahmedabad.
- Company maintains a small market capitalization of ₹26 Cr with zero TTM revenue.
- Financial context shows a significant TTM net loss of ₹56 Cr and a negative ROCE of -105.0%.
Johnson Pharmacare Ltd has scheduled a board meeting for August 13, 2026, to consider and approve its unaudited standalone financial results for the quarter ended June 30, 2026. The company is currently in a precarious financial position with TTM revenue of Rs 0 and a TTM net loss of Rs 56 crore. The trading window for insiders has been closed since July 1, 2026, and will reopen 48 hours after the results are announced. Investors should note the company's negative net worth and high debt of Rs 21 crore relative to its Rs 26 crore market capitalization.
- Board meeting scheduled for August 13, 2026, to approve Q1 FY27 results
- Trading window closed from July 1, 2026, until 48 hours post-result declaration
- Company reported zero revenue (Rs 0.0 cr) for the previous four consecutive quarters
- TTM net loss stands at Rs 56 crore as of the March 2026 quarter
- Debt levels are high at Rs 21 crore against a market cap of Rs 26 crore
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
